BioRestorative rises on preliminary data from back pain therapy candidate

Biorestorative Therapies

05/02/2024 16:02

** Shares of cell therapy developer BioRestorative Therapies
Inc  BRTX.O   rise 8.2% to $3  
    ** Co announces positive preliminary data from its ongoing
mid-stage study testing its lead candidate BRTX-100
     ** Results from the study collected at weeks 26 and 52
showed that the therapy helped in reducing lower back pain
measured against various pain and function scales- BRTX  
    ** BRTX says the therapy showed no notable safety signals 
    ** BRTX-100 is being studied as a treatment for chronic
lumbar disc disease, which occurs when a disc in the lower back
area of the spine bulges out, causing back pain 
    ** Stock fell 9% in the last 12 months 
    

 (Reporting by Sneha  S K)
 ((Sneha.SK@thomsonreuters.com;))